Computerized Depression Intervention in Veterans

This study is testing a computer program called Deprexis, which is an online treatment for symptoms of depression. It's designed to help Veterans who have mild to moderate depression and problems with daily functioning. Researchers want to see how much Deprexis can improve depression symptoms and daily functioning. You might be able to join if you are a Veteran, 18 or older, have reliable internet access, and your depression is not very severe. The study aims to enroll 152 participants. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 152 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 16 weeks after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06217198

A Computerized Depression Intervention in Veterans

Recruiting
NAAges 18+InterventionalTreatment
VA Office of Research and Development
~152 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:Deprexis

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Quick Inventory of Depressive Symptomatology (Self-Report; QIDS-SR-16) Change
Measured over Baseline, Post-Treatment (week 8), Follow-up (week 16)
+2 more outcomes measured
Depression

NCT06217198

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX

    Waco, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Rahel R Pearson, PhD · PRINCIPAL_INVESTIGATOR · Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

able to comprehend and sign the informed consent form
have reliable access to the internet and a computer, tablet and/or smartphone
exhibit mild or moderate, but not very severe, levels of depression
stable on psychotropic medications

Exclusion

endorse any positive symptoms of a psychotic disorder
screen positive for Bipolar I Disorder
report current suicidal risk
  • Quick Inventory of Depressive Symptomatology (Self-Report; QIDS-SR-16) ChangeBaseline, Post-Treatment (week 8), Follow-up (week 16)

    The Quick Inventory of Depressive Symptomatology (Self-Report; QIDS-SR-16) is a 16-item self-report measure of depressive symptom severity. This brief measure assesses the 9 DSM-IV symptom criterion domains for depression and has been shown to be highly reliable, internally consistent and sensitive to symptom change. QIDS-SR-16 scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

  • World Health Organization Disability Assessment Schedule-II (WHODAS) ChangeBaseline, Post-Treatment (week 8), Follow-up (week 16)

    The World Health Organization Disability Assessment Schedule-II (WHODAS) is a 36-item questionnaire assessing functional disability across 7 domains (understanding and communicating, getting around, getting along with people, life activities, work, participation in society, self-care) as well as a total score. The WHODAS has high test-retest reliability (r=0.98) and concurrent and construct validity. WHODAS scores range from 0 to 100, with higher scores indicating greater disability

  • The Sheehan Disability Scale (SDS) ChangeBaseline, Post-Treatment (week 8), Follow-up (week 16)

    The Sheehan Disability Scale (SDS) is a 3-item self-report measure of symptom-related disability, which has been used in previous Deprexis trials. The SDS was developed as a global measure of the impact of mental illness on work/school activities, family relationships and social functioning. The SDS has been found to be internally consistent, reliable and to have high construct validity and to be sensitive to treatment effects. SDS scores range from 0 to 30, with higher scores indicating greater functional impairment.